| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.5 | 1.4 |
| Net income | -19.2 | -16.3 |
| EPS (diluted, $ a share) | $-0.88 | $-0.75 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -60.1% |
|---|
10-Q filed with the SEC, NASDAQ: AARD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aardvark Therapeutics, Inc.: key numbers
- Share price
- $1.26Close, Nov 16
- Market cap
- $27.6M
- Shares outstanding
- 21.89MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aardvark Therapeutics, Inc.
All →Aardvark Therapeutics Financial Results
Aardvark Therapeutics reported Q3 2026 financial results and announced that the FDA has lifted the clinical hold on its lead candidate ARD-101 for Prader-Willi Syndrome. The company ended the quarter with $60.3 million in cash, which is expected to fund operations through 2027 as it prepares for a clinical development meeting with the FDA in early 2027.
- Term
- Q3 2026
“The lifting of the clinical hold and the FDA’s agreement that we may conduct an open-label trial at 200 mg twice daily are important steps toward resuming clinical development of ARD-101 in PWS. We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”
Tien Lee, M.D., Founder and Chief Executive Officer
Aardvark Therapeutics Clinical Trial Data
Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.
Aardvark Therapeutics Business Update
The FDA has lifted the clinical hold on Aardvark Therapeutics' Investigational New Drug (IND) application for ARD-101, which is being developed to treat hyperphagia in Prader-Willi Syndrome. The hold was originally placed in May 2026 following reversible ECG changes in healthy volunteers, but subsequent studies showed no cardiac events at therapeutic doses. The company plans to resume clinical development following further alignment with the FDA on Phase 3 trial design.
- Counterparty
- FDA
Aardvark Therapeutics Leadership Change
Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director to its Board of Directors, effective October 7, 2026. Dr. Zhang brings over 25 years of experience in clinical strategy and biostatistics from roles at Abivax, Alumis, and MyoKardia. As a non-employee director, he will receive an annual cash retainer of $40,000 and an initial stock option grant valued at $500,000.